Yang, Y.; Pearson, R.M.; Lee, O.; Lee, C.W.; Chatterton, R.T.; Khan, S.A.; Hong, S. Dendron-based micelles for topical delivery of endoxifen: A potential chemo-preventive medicine for breast cancer. Adv. Funct. Mater. 2014, 24, 2442-2449. [CrossRef]...
"For women with breast cancer that has spread, 70 percent of those patients develop metastasis to the bone," said senior author Katherine N. Weilbaecher, MD, a professor of medicine. "Bone metastases destroy the bone, causing fractures and pain. If the tumors reach the spine, it can cause...
This finding is bolstered by another recent study conducted at the Albert Einstein College of Medicine and published in Science Translational Medicine, which showed a similar result using imaging techniques to observe the tumor in mice, Hai said. Second, the Ohio State researchers found that, beyon...
The findings were firstpresentedat the 2019 European Society of Medical Oncology (ESMO 2019) annual meeting, and simultaneouslypublished onlinein theNew England Journal of Medicine. SUGGESTED for you In Part 1a of the trial, 793 patients were randomly assigned to receive either the combination of n...
The results of the so-calledTAILORxtrial were presented yesterday at the annual meeting of the American Society of Clinical Oncology and concurrently published in the New England Journal of Medicine. Breast cancer types The study looked at over 10,000 women with one specific type o...
K Rashid,H Sean,VG Monica - 《American Journal of Physical Medicine & Rehabilitation》 被引量: 0发表: 2024年 Editorial: "Global Challenges in Radiation Oncology" (CCRN), the US Cancer Disparities Research Partnership (CDRP), training radiation oncologists in underserved parts of the world, and...
- 《Journal of Translational Medicine》 被引量: 167发表: 2010年 Combined chemoimmunotherapy and radiation therapy of inflammatory breast carcinoma Thirty-two patients with a diagnosis of primary inflammatory breast carcinoma were treated with combination chemoimmunotherapy consisting of 5-fluorouracil... ...
The first results from RxPONDER provide insight – and controversy – regarding the need for chemotherapy by women with node-positive, low-risk HR+, HER2- breast cancer.
It also includes oral versions of these drugs if your doctor could have given you an intravenous dose but decided to provide you with a pill instead, and the medicine is taken within 48 hours of your cancer treatment. Part D covers cancer drugs that are not covered by Part B, including...
Researchers at the Stanford University School of Medicine have demonstrated a method of forecasting which breast cancer patients will suffer heart problems from a commonly used chemotherapy drug. The researchers also found that a class of medications already approved by the Food and Drug Administration ...